-
TREATMENT PATTERN, HEALTHCARE RESOURCE UTILIZATION AND COST OF PEDIATRIC PATIENTS WITH ATOPIC DERMATITIS: A CLAIMS DATA ANALYSIS IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
HEALTH AND ECONOMIC IMPACT OF SALT AND ALCOHOL REDUCTION STRATEGIES FOR HYPERTENSION AND CARDIOVASCULAR DISEASE PREVENTION IN GHANA
Mar 18, 2026, 21:38 PM -
CARDIOMETABOLIC RISK TRAJECTORIES ON AND AFTER ANTI-OBESITY MEDICATION USE: A CLAIMS-BASED ANALYSIS
Mar 18, 2026, 21:38 PM -
REAL-WORLD IMPACT OF ANTI-AMYLOID THERAPY IN ALZHEIMER’S DISEASE: AN INTEGRATED ANALYSIS OF 100% MEDICARE FFS CLAIMS LINKED WITH LABORATORY, ELECTRONIC MEDICAL RECORDS, AND PATIENT-REPORTED OUTCOMES MEASURES
Mar 18, 2026, 21:38 PM -
PSYCHOMETRIC PROPERTIES OF THE MULTIPLE MYELOMA SYMPTOM AND IMPACT QUESTIONNAIRE (MYSIM-Q) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): ANALYSIS OF THE MAJESTEC-3 STUDY
Mar 18, 2026, 21:38 PM -
GOVERNING RWD- AND GENAI-ENABLED RWE: PRACTICAL, AUDITABLE CONTROLS FOR FASTER—YET TRUSTWORTHY—EVIDENCE GENERATION
Mar 18, 2026, 21:38 PM -
FROM EVIDENCE TO APPRAISAL: BEST-PRACTICE CONSIDERATIONS FOR EXTERNAL CONTROL ARMS BASED ON CANADIAN REGULATORY AND HTA REVIEWS
Mar 18, 2026, 21:38 PM -
PROSPECTIVE ASSESSMENT OF OPERATIONAL EFFICIENCY AND QUALITY PARAMETERS OF BLOOD UNITS PROCESSED BY MANUAL VERSUS FULLY AUTOMATED WHOLE BLOOD SYSTEMS IN A REGIONAL ARGENTINE BLOOD BANK
Mar 18, 2026, 21:38 PM -
COST PER MONTH OF PROGRESSION FREE SURVIVAL ANALYSIS OF THE CURRENTLY AVAILABLE TREATMENTS FOR PATIENTS WITH REFRACTORY/ RELAPSED MANTLE CELL LYMPHOMA IN THE BRAZILIAN HEALTH SYSTEM
Mar 18, 2026, 21:38 PM -
TRENDS AND POSTMARKETING OUTCOMES OF ACCELERATED APPROVALS (AAS) IN FDA NEW DRUG APPLICATIONS AND BIOLOGIC LICENSE APPLICATIONS (NDAS/BLAS) FROM 1992-2025
Mar 18, 2026, 21:38 PM -
TRENDS IN LDL CHOLESTEROL LEVELS AMONG MEDICARE ADVANTAGE BENEFICIARIES: 2015-2024
Mar 18, 2026, 21:38 PM -
ON-DEMAND TREATMENTS FOR HEREDITARY ANGIOEDEMA AND HEALTHCARE RESOURCE UTILIZATION IN PEDIATRIC (2-11 YEARS) PATIENTS: A US CLAIMS DATABASE ANALYSIS
Mar 18, 2026, 21:38 PM -
IMPACT OF VARIANCE IN COHORT PHENOTYPE DEFINITIONS ON REAL-WORLD RESEARCH: AN ASSESSMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) DEFINITIONS ON REAL-WORLD DATA
Mar 18, 2026, 21:38 PM -
POPULATION-LEVEL IMPACT OF EMICIZUMAB IN MODERATE-SEVERE HEMOPHILIA A: A TREATMENT IMPACT MODEL
Mar 18, 2026, 21:38 PM -
DOES ONE SIZE FIT ALL? UTILITY MEASUREMENT GUIDANCE ACROSS HTAS IN THE ERA OF JOINT CLINICAL ASSESSMENT AND INTERNATIONAL REFERENCE PRICING
Mar 18, 2026, 21:38 PM -
WHEN EXACTLY WERE YOU BORN? COMPARING EXACT DATE OF BIRTH AND DATE OF BIRTH PROXIES IN THE MARKETSCAN MULTI-STATE MEDICAID DATABASE
Mar 18, 2026, 21:38 PM -
A CAUSAL MULTISTATE FRAMEWORK FOR TREATMENT SWITCHING IN NETWORK META-ANALYSES OF TIME-TO-EVENT OUTCOMES IN ONCOLOGY
Mar 18, 2026, 21:38 PM -
APPLYING MARGIN-BASED HEALTH ECONOMIC MODELING TO DIABETES TECHNOLOGIES UNDER THE 2026 CMS ACCESS MODEL: AN ILLUSTRATIVE FRAMEWORK
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS ANALYSIS OF ¹77LU-PSMA-617 VERSUS CABAZITAXEL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: AN ANALYSIS BASED ON REAL-WORLD DATA AND THERAP TRIAL
Mar 18, 2026, 21:38 PM -
US PAYER PERSPECTIVES ON DRUG MANUFACTURER READINESS FOR ARTIFICIAL INTELLIGENCE
Mar 18, 2026, 21:38 PM
